| Study name |
Setting |
Treatment |
RR (CR+PR) (%) |
mPFS
(months) |
mOS
(months) |
AVF2107g
(phase III) |
1st-line
(n=923) |
IFL+BV
IFL
5-FU/LV+BV |
44.8 (p=0.007)
34.8
40.0 |
10.6 (p<0.001)
6.2
8.8 |
20.3
15.6
18.3 |
N0 169963
(phase III) |
1st-line
(n=1400) |
XELOX/FOLFOX+BV
XELOX/FOLFOX |
47
49 |
9.4 (p<0.001)
8.0 |
21.3
19.9 |
E4599
(phase III) |
1st-line
(n=850) |
PTX/CBDCA+BV
PTX/CBDCA |
35 (p<0.001)
15 |
6.2 (p<0.001)
4.4 |
12.3 (p=0.003)
10.3 |
AVAiL
(phase II) |
1st-line
(n=1043) |
GEM/CDDP+BV(15mg/kg)
GEM/CDDP+BV(7.5mg/kg)
GEM/CDDP |
30.4 (p= 0.0023)
34.1 (p<0.0001)
20 |
6.5 (p=0.03)
6.7 (p=0.003)
6.1 |
N.R.
N.R.
N.R. |
RR: response rate, CR: complete response, PR: partial response, mPFS: median progression free survival,
mOS: median overall survival, N.R.: not reported. BV:
bevacizumab, IFL: irinotecan/5-FU/leucovorin,
XELOX: oxaliplatine/capecitabine, FOLFOX: oxaliplatine/5-FU/leucovorin, PTX: paclitaxel, CBDCA: carboplatin,
GEM:
gemcitabine, CDDP: cisplatin |
